Partnership to supercharge LVMH Recherche with Integrated Biosciences’ innovative AI and synthetic biology platform for targeting skin aging
The company plans to advance Ropanicant into double-blind, placebo-controlled Phase-2b clinical study in MDD patients, anticipated to start in early 2025
The R&D centre is mainly dedicated to the Process R&D of New Chemical Entities (NCE) development projects
Lupin has received US$ 25 million from AbbVie for initiation of Phase 1 clinical studies successfully
The company has successfully developed Methyl salicylate using Flow Chemistry and successfully erected a Flow reactor at Jhagadia plant and expects to start production from Q3 FY23
Advancing to IND-enabling studies with multiple drug candidates
Highlighted as game changer in drug development & delivery special feature on innovative technologies for improving drug solubility and bioavailability
Arum's research focuses on the discovery of new chemical entities that will act as effective therapies for drug-resistant cancers
These new chemical entities are covered by composition of matter patent applications. Financial terms of the deal were not disclosed
Agreement builds on 15 years of successful collaboration between AbbVie and Richter, including globally launched cariprazine products
Subscribe To Our Newsletter & Stay Updated
